AxoGen (AXGN) to Announce Quarterly Earnings on Wednesday

AxoGen (NASDAQ:AXGN) is projected to post its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect AxoGen to post earnings of $0.09 per share and revenue of $67.0990 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). AxoGen had a negative return on equity of 9.63% and a negative net margin of 13.21%.The firm had revenue of $61.46 million for the quarter, compared to the consensus estimate of $57.85 million. On average, analysts expect AxoGen to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AxoGen Stock Performance

Shares of AXGN stock opened at $41.14 on Tuesday. The business’s 50-day moving average price is $42.16 and its 200-day moving average price is $37.16. AxoGen has a 12 month low of $12.39 and a 12 month high of $46.95. The company has a current ratio of 7.10, a quick ratio of 5.33 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -64.28 and a beta of 1.09.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Zacks Research raised AxoGen from a “strong sell” rating to a “hold” rating in a research report on Friday, May 29th. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a research report on Friday, May 29th. HC Wainwright lifted their price objective on AxoGen from $39.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Canaccord Genuity Group upped their target price on AxoGen from $45.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Sunday. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, AxoGen currently has an average rating of “Moderate Buy” and a consensus target price of $46.50.

Insider Transactions at AxoGen

In related news, Director Kathy Johnson Weiler sold 16,344 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $44.09, for a total transaction of $720,606.96. Following the sale, the director owned 16,344 shares in the company, valued at $720,606.96. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amy Mcbride Wendell sold 1,647 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $42.60, for a total value of $70,162.20. Following the sale, the director directly owned 93,826 shares of the company’s stock, valued at $3,996,987.60. This represents a 1.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 29,041 shares of company stock valued at $1,268,792. Corporate insiders own 2.44% of the company’s stock.

Hedge Funds Weigh In On AxoGen

Several institutional investors have recently added to or reduced their stakes in AXGN. Royal Bank of Canada boosted its holdings in shares of AxoGen by 14.2% during the 1st quarter. Royal Bank of Canada now owns 38,043 shares of the medical equipment provider’s stock worth $704,000 after buying an additional 4,723 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of AxoGen by 45.3% in the 1st quarter. AQR Capital Management LLC now owns 23,917 shares of the medical equipment provider’s stock valued at $442,000 after acquiring an additional 7,453 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of AxoGen by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,185 shares of the medical equipment provider’s stock valued at $466,000 after acquiring an additional 1,057 shares during the period. Jones Financial Companies Lllp lifted its position in shares of AxoGen by 104,810.0% during the 1st quarter. Jones Financial Companies Lllp now owns 10,491 shares of the medical equipment provider’s stock valued at $194,000 after acquiring an additional 10,481 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in AxoGen by 37.3% during the second quarter. JPMorgan Chase & Co. now owns 379,070 shares of the medical equipment provider’s stock worth $4,113,000 after acquiring an additional 103,072 shares in the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.